Estrella Immunopharma, Inc. (ESLA)
ESLA moved a median of 0.00% 30 minutes after news, and -0.14% by the close. How ESLA actually reacts to news — the realized, point-in-time move the market made, measured across 99 labeled events over the last three years with zero look-ahead.
ESLA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 35% | 66 |
| 30-min | 0.00% | 36% | 86 |
| 60-min | 0.00% | 38% | 94 |
| to close | -0.14% | 49% | 97 |
| Middle 50% of ESLA reactions | -2.29% to +2.27% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 99 |
Half of all Estrella Immunopharma, Inc. news events land between -2.29% and +2.27% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ESLA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ESLA's baseline. Nothing else.
Recent ESLA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase | Press release | Business Wire | -7.39% | -15.69% | |
| Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma | Press release | Business Wire | +3.19% | +72.64% | |
| Form 8-K Estrella Immunopharma, For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | +0.15% | -6.04% | |
| Form 8-K Estrella Immunopharma, For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.91% | |
| Form 10-Q Estrella Immunopharma, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.14% | |
| Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma | Press release | Business Wire | +0.00% | -2.21% | |
| Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma | Press release | Business Wire | — | -0.14% | |
| Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma | Press release | Business Wire | — | +4.09% | |
| Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma | Press release | Business Wire | +2.63% | +2.63% | |
| ESLA: Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma, Inc. Stockholders | Press release | GlobeNewswire | -2.76% | +4.79% | |
| Form 8-K Estrella Immunopharma, For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -3.38% | -5.07% | |
| Form DEF 14A Estrella Immunopharma, For: Jun 29 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +3.64% | |
| Form 10-Q Estrella Immunopharma, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.61% | |
| Form NT 10-Q Estrella Immunopharma, For: Mar 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | -2.61% | |
| Estrella Immunopharma to Participate in the D. Boral Capital Global Conference | Press release | Business Wire | +0.00% | -6.23% | |
| Form 10-K/A Estrella Immunopharma, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.51% | +1.24% | |
| Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research | Press release | Business Wire | — | -5.56% | |
| Form 10-K Estrella Immunopharma, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.64% | -1.82% | |
| Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® | Press release | Business Wire | +1.49% | +6.34% | |
| Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR® | Press release | Business Wire | +6.42% | +7.34% | |
| Form EFFECT Estrella Immunopharma, | SEC filing · Form EFFECT | SEC EDGAR | +0.96% | -1.92% | |
| Form S-1/A Estrella Immunopharma, | SEC filing · Form S-1 | SEC EDGAR | -0.22% | +4.60% | |
| Form S-1/A Estrella Immunopharma, | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -5.52% | |
| Form 8-K Estrella Immunopharma, For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | — | +7.43% | |
| Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement | Press release | Business Wire | -2.40% | -6.16% | |
| Form 8-K Estrella Immunopharma, For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.13% | |
| Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules | Press release | Business Wire | +5.71% | -5.00% | |
| Form S-1 Estrella Immunopharma, | SEC filing · Form S-1 | SEC EDGAR | -1.77% | -9.47% | |
| Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation | Press release | Business Wire | +1.80% | +15.57% | |
| Form 8-K Estrella Immunopharma, For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | +1.80% | +15.57% | |
| Form 10-Q Estrella Immunopharma, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.66% | — | |
| Form 8-K Estrella Immunopharma, For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | +7.33% | |
| Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients | Press release | Business Wire | -3.96% | +5.17% | |
| Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements | Press release | Business Wire | +0.07% | +5.26% | |
| Form 8-K Estrella Immunopharma, For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | -1.65% | -4.96% | |
| Form 8-K Estrella Immunopharma, For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -3.23% | -3.25% | |
| Form 10-Q Estrella Immunopharma, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Estrella Immunopharma, For: Aug 01 | SEC filing · Form 8-K | SEC EDGAR | — | +2.52% | |
| Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma | Press release | Business Wire | -4.19% | +10.38% | |
| Form 8-K Estrella Immunopharma, For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | -4.19% | +10.38% | |
| Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing | Press release | Business Wire | -5.00% | -24.16% | |
| Form 8-K Estrella Immunopharma, For: May 30 | SEC filing · Form 8-K | SEC EDGAR | -5.00% | -24.16% | |
| Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas | Press release | Business Wire | +0.00% | +5.16% | |
| Form 8-K Estrella Immunopharma, For: May 29 | SEC filing · Form 8-K | SEC EDGAR | +2.30% | +4.35% | |
| Form 10-Q Estrella Immunopharma, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.13% | -8.73% | |
| Form 8-K Estrella Immunopharma, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | — | +4.63% | |
| Form 10-KT Estrella Immunopharma, For: Dec 31 | SEC filing · Form 10-KT | SEC EDGAR | — | -3.45% | |
| Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners | Press release | Business Wire | — | +1.96% | |
| Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort | Press release | Business Wire | -1.75% | -12.43% | |
| Form 8-K Estrella Immunopharma, For: Feb 21 | SEC filing · Form 8-K | SEC EDGAR | -1.75% | -12.43% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ESLA section they belong to.
Where else ESLA is measured.
ESLA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Estrella Immunopharma, Inc.'s median reaction calculated?
Every labeled ESLA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 99 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of ESLA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ESLA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.